Join
Live feed
·
PRReleasevia Quantisnow
Vertex Pharmaceuticals Incorporated logo

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

ByQuantisnow·Wall Street's wire, on your screen.
VRTX· Vertex Pharmaceuticals Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VRTX (Vertex Pharmaceuticals Incorporated) and more on Quantisnow.